Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …

Lenacapavir: a first-in-class HIV-1 capsid inhibitor : Current Opinion in HIV and AIDS
Lenacapavir: a first-in-class HIV-1 capsid inhibitor : Current Opinion in HIV and AIDS Log in or …

Lenacapavir (Sunlenca®) is a long-acting capsid inhibitor of human immunodeficiency virus
type 1 (HIV-1) being developed by Gilead Sciences Inc. It is available as an oral tablet and …

Human immunodeficiency virus (HIV) infection is now recognized as a chronic illness.
Although the success of highly active antiretroviral therapy is beyond question, several …

Background Antiretroviral agents with novel mechanisms and dosing intervals could expand
treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes …

In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT
(zidovudine, 3′-azido-2′, 3′-dideoxythymidine), was described. It was the first of 25 …

In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then
tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti …

More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the
treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing …

There are now exactly 20 anti-HIV drugs licenced (approved) for clinical use, and> 30 anti-
HIV compounds under (pre) clinical development. The licenced anti-HIV drugs fall into five …

Twenty-five years after the discovery of the therapeutic activity of azidothymidine (AZT), the
first antiretroviral drug used in the clinic, infection with the human immunodeficiency virus …